Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1105 to 1109 of 1109 entries
Sorted by: Best Match Show Resources per page
Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.

Epigenetics

Dougherty U, Mustafi R, Zhu H, Zhu X, Deb D, Meredith SC, Ayaloglu-Butun F, Fletcher M, Sanchez A, Pekow J, Deng Z, Amini N, Konda VJ, Rao VL, Sakuraba A, Kwesi A, Kupfer SS, Fichera A, Joseph L, Hart J, He F, He TC, West-Szymanski D, Li YC, Bissonnette M.
PMID: 33356812
Epigenetics. 2021 Dec;16(12):1317-1334. doi: 10.1080/15592294.2020.1863117. Epub 2020 Dec 28.

Because ADAM17 promotes colonic tumorigenesis, we investigated potential miRNAs regulating ADAM17; and examined effects of diet and tumorigenesis on these miRNAs. We also examined pre-miRNA processing and tumour suppressor roles of several of these miRNAs in experimental colon cancer....

Cite
Dougherty U, Mustafi R, Zhu H, et al. Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics. 2020;16(12):1317-1334doi: 10.1080/15592294.2020.1863117.
Dougherty, U., Mustafi, R., Zhu, H., Zhu, X., Deb, D., Meredith, S. C., Ayaloglu-Butun, F., Fletcher, M., Sanchez, A., Pekow, J., Deng, Z., Amini, N., Konda, V. J., Rao, V. L., Sakuraba, A., Kwesi, A., Kupfer, S. S., Fichera, A., Joseph, L., Hart, J., He, F., He, T. C., West-Szymanski, D., Li, Y. C., & Bissonnette, M. (2021). Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics, 16(12), 1317-1334. https://doi.org/10.1080/15592294.2020.1863117
Dougherty, Urszula, et al. "Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer." Epigenetics vol. 16,12 (2021): 1317-1334. doi: https://doi.org/10.1080/15592294.2020.1863117
Dougherty U, Mustafi R, Zhu H, Zhu X, Deb D, Meredith SC, Ayaloglu-Butun F, Fletcher M, Sanchez A, Pekow J, Deng Z, Amini N, Konda VJ, Rao VL, Sakuraba A, Kwesi A, Kupfer SS, Fichera A, Joseph L, Hart J, He F, He TC, West-Szymanski D, Li YC, Bissonnette M. Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer. Epigenetics. 2021 Dec;16(12):1317-1334. doi: 10.1080/15592294.2020.1863117. Epub 2020 Dec 28. PMID: 33356812.
Copy Download .nbib Format: NLM
Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France.

Vaccine

Ribera-Cano A, Dupont M, Houzé-Cerfon CH, Houzé-Cerfon V, Hart A, Hertelendy AJ, Ciottone G, Bounes V.
PMID: 34782160
Vaccine. 2021 Dec 17;39(51):7441-7445. doi: 10.1016/j.vaccine.2021.10.080. Epub 2021 Nov 03.

AIM OF THE STUDY: In the context of the worldwide vaccination campaign against COVID-19, France has been deploying multiple sites for mass vaccination. This study aimed to assess the perceived usefulness of a prototype decontamination mobile unit (UMDEO) for...

Cite
Ribera-Cano A, Dupont M, Houzé-Cerfon CH, et al. Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France. Vaccine. 2021;39(51):7441-7445doi: 10.1016/j.vaccine.2021.10.080.
Ribera-Cano, A., Dupont, M., Houzé-Cerfon, C. H., Houzé-Cerfon, V., Hart, A., Hertelendy, A. J., Ciottone, G., & Bounes, V. (2021). Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France. Vaccine, 39(51), 7441-7445. https://doi.org/10.1016/j.vaccine.2021.10.080
Ribera-Cano, Anna, et al. "Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France." Vaccine vol. 39,51 (2021): 7441-7445. doi: https://doi.org/10.1016/j.vaccine.2021.10.080
Ribera-Cano A, Dupont M, Houzé-Cerfon CH, Houzé-Cerfon V, Hart A, Hertelendy AJ, Ciottone G, Bounes V. Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France. Vaccine. 2021 Dec 17;39(51):7441-7445. doi: 10.1016/j.vaccine.2021.10.080. Epub 2021 Nov 03. PMID: 34782160; PMCID: PMC8563340.
Copy Download .nbib Format: NLM
Are we addressing the top 10 research priorities in IBD?.

Frontline gastroenterology

Geldof J, LeBlanc JF, Lucaciu L, Segal J, Lees CW, Hart A.
PMID: 34917313
Frontline Gastroenterol. 2020 Nov 11;12(7):564-569. doi: 10.1136/flgastro-2020-101579. eCollection 2021.

BACKGROUND: Since publication of the top 10 research priorities in inflammatory bowel disease (IBD) based on the James Lind Alliance Priority Setting Partnership, the question remains whether this has influenced the IBD-research landscape. This study aimed to create an...

Cite
Geldof J, LeBlanc JF, Lucaciu L, et al. Are we addressing the top 10 research priorities in IBD?. Frontline Gastroenterol. 2020;12(7):564-569doi: 10.1136/flgastro-2020-101579.
Geldof, J., LeBlanc, J. F., Lucaciu, L., Segal, J., Lees, C. W., & Hart, A. (2021). Are we addressing the top 10 research priorities in IBD?. Frontline gastroenterology, 12(7), 564-569. https://doi.org/10.1136/flgastro-2020-101579
Geldof, Jeroen, et al. "Are we addressing the top 10 research priorities in IBD?." Frontline gastroenterology vol. 12,7 (2021): 564-569. doi: https://doi.org/10.1136/flgastro-2020-101579
Geldof J, LeBlanc JF, Lucaciu L, Segal J, Lees CW, Hart A. Are we addressing the top 10 research priorities in IBD?. Frontline Gastroenterol. 2020 Nov 11;12(7):564-569. doi: 10.1136/flgastro-2020-101579. eCollection 2021. PMID: 34917313; PMCID: PMC8640395.
Copy Download .nbib Format: NLM
Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization.

Scientific reports

Uematsu S, Sakaguchi H, Sayanagi K, Ikuno Y, Yokoyama A, Asai T, Fukushima Y, Hara C, Sakimoto S, Nishida K.
PMID: 34754047
Sci Rep. 2021 Nov 09;11(1):21947. doi: 10.1038/s41598-021-01557-z.

Although choriocapillaris flow deficit (CFD) around choroidal neovascularization (CNV) is less associated with CNV activity in myopic eyes, no reports are investigating its size as an indicator of CNV activity. We investigated the relationship between CFD and high myopia-related...

Cite
Uematsu S, Sakaguchi H, Sayanagi K, et al. Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization. Sci Rep. 2021;11(1):21947doi: 10.1038/s41598-021-01557-z.
Uematsu, S., Sakaguchi, H., Sayanagi, K., Ikuno, Y., Yokoyama, A., Asai, T., Fukushima, Y., Hara, C., Sakimoto, S., & Nishida, K. (2021). Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization. Scientific reports, 11(1), 21947. https://doi.org/10.1038/s41598-021-01557-z
Uematsu, Sato, et al. "Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization." Scientific reports vol. 11,1 (2021): 21947. doi: https://doi.org/10.1038/s41598-021-01557-z
Uematsu S, Sakaguchi H, Sayanagi K, Ikuno Y, Yokoyama A, Asai T, Fukushima Y, Hara C, Sakimoto S, Nishida K. Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization. Sci Rep. 2021 Nov 09;11(1):21947. doi: 10.1038/s41598-021-01557-z. PMID: 34754047; PMCID: PMC8578547.
Copy Download .nbib Format: NLM
Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?.

British journal of pharmacology

Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC.
PMID: 34363224
Br J Pharmacol. 2021 Aug 06; doi: 10.1111/bph.15647. Epub 2021 Aug 06.

Introduced less than two decades ago, glucagon-like peptide-1 receptor agonists rapidly reshaped the field of Type 2 diabetes mellitus (T2DM) care by providing glycaemic control in tandem with weight loss. However, FDA-approved GLP-1 receptor agonists are often accompanied by...

Cite
Borner T, Tinsley IC, Doyle RP, et al. Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. Br J Pharmacol. 2021;doi: 10.1111/bph.15647.
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2021). Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. British journal of pharmacology, . https://doi.org/10.1111/bph.15647
Borner, Tito, et al. "Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?." British journal of pharmacology vol. (2021). doi: https://doi.org/10.1111/bph.15647
Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC. Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. Br J Pharmacol. 2021 Aug 06; doi: 10.1111/bph.15647. Epub 2021 Aug 06. PMID: 34363224.
Copy Download .nbib Format: NLM
Showing 1105 to 1109 of 1109 entries